Helicobacter pylori Treatment Success Rate amongst Rwandan Endoscopy Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201804003257400

Enrollment

244

Registered

2018-03-28

Start date

2015-11-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System H. Pylori H. pylori

Interventions

omeprazole+ amoxicillin+ clarithromycin (CLARITHRO)

omeprazole+ amoxicillin+ ciprofloxacin (CIPRO)

omeprazole+ amoxicillin+ metronidazole (METRO)

omeprazole+ amoxicillin+ ciprofloxacin+Doxycyclin) (CIPRO-Plus)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged 21 years and above Referred for upper gastro-intestinal endoscopy at Butare University Teaching Hospital Positive modified rapid urease test on endoscopic biopsies study medications

Exclusion criteria

Exclusion criteria: Pregnant women Patients with suspected malignancies on endoscopy Patients with known allergy to one of the

Design outcomes

Primary

Measure	Time frame
Evidence of H. Pylori eradication ;Health related quality of life score change by SF-NDI	—

Countries

Rwanda

Contacts

Public ContactJean Damascene;Celestin Kabakambira;Hategeka

Research Fellow/ NIH;Epidemiologist

damaskabakambira@gmail.com;celestin.hategeka@gmail.com+12023447389;+17789907941

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026